Pricing:

Single User Licence
$4200
Multi User License Upto 5 Users
$6500
Enterprise License
$8400
Download Sample Add to Cart Buy Now

Don’t see what you are Looking For:

We can create a custom report for you, please fill the form below

Download Free Sample Now

Global Venous Stents Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Technology;

Iliac Vein Stent Technology and Wallstent Technology

By Stent Design;

Braided, Laser-Cut, Open-Cell, and Closed-Cell

By Material;

Nitinol, Elgiloy, and Stainless Steel

By Disease;

Chronic Deep Vein, Thrombosis, Post Thrombotic Syndrome, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)

Report ID: Rn159396315 Published Date: May, 2025 Updated Date: June, 2025

Download Free Sample Now Request Customized Sample

Venous Stents Market Overview

Venous Stents Market (USD Million)

Venous Stents Market was valued at USD 4,801.11 million in the year 2024. The size of this market is expected to increase to USD 8,520.60 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.5%.

Global Venous Stents Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 8.5 %

Study Period	2025 - 2031
Base Year	2024
CAGR (%)	8.5 %
Market Size (2024)	USD 4,801.11 Million
Market Size (2031)	USD 8,520.60 Million
Market Concentration	Medium
Report Pages	399

4,801.11

2024

8,520.60

2031

Major Players

Gore Medical
Cook Medical
Boston Scientific Corporation
Becton, Dickinson and Company
Medtronic Plc

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Venous Stents Market

Fragmented - Highly competitive market without dominant players

The Venous Stents Market is witnessing steady expansion as healthcare systems increasingly adopt these devices for managing chronic venous blockages and deep vein thrombosis. These conditions demand long-term solutions, and venous stents provide a reliable, minimally invasive approach. Around 65% of clinical usage is associated with treating venous insufficiency, illustrating their integral role in vascular therapy.

Advancements in Stent Engineering
Innovations in stent technology, including advanced alloys and self-expanding designs, are transforming the effectiveness of venous stents. These improvements are tailored to match the dynamic environment of venous circulation. Over 40% of newer models now incorporate cutting-edge biomaterials that enhance patient compatibility and reduce procedural complications.

Minimally Invasive Procedures on the Rise
A strong trend toward minimally invasive vascular procedures is propelling the adoption of venous stents. These methods offer quicker recovery times and less postoperative discomfort. Presently, about 55% of patients undergoing treatment for venous blockages benefit from stenting methods, highlighting a shift in clinical strategies.

Research Initiatives and Clinical Support
Increased focus on clinical research and favorable healthcare guidelines are reinforcing the market potential of venous stents. Nearly 45% of ongoing vascular research involves testing the performance and safety of venous stents, reflecting a growing confidence in their clinical value. Such developments are expected to further solidify their role in modern vascular care.

Venous Stents Market Recent Developments

In October 2023, Philips announced results from the VIVID trial, which evaluated the safety and efficacy of the Duo venous stent system. The VIVID trail was a multicenter, single-arm study that enrolled 162 patients with non-thrombotic, acute thrombotic, or chronic post-thrombotic clinically significant venous outflow obstruction, across 30 sites in the United States and Poland.
In May 2022, Becton, Dickinson, and Company declared that its Venovo venous stent system was re-launched in the U.S. market after a recall initiated in May 2021, outlining risks associated with stent migration.

Venous Stents Market Segment Analysis

In this report, the Venous Stents Market has been segmented by Technology, Stent Design, Material, Disease and Geography.

Venous Stents Market, Segmentation by Technology

The Venous Stents Market has been segmented by Technology into Iliac Vein Stent Technology, and Wallstent Technology.

Iliac Vein Stent Technology

Iliac Vein Stent Technology is primarily utilized to treat iliac vein obstructions, including conditions like May-Thurner Syndrome and post-thrombotic syndrome. T. The growth is attributed to the rising cases of deep vein thrombosis (DVT) and chronic venous insufficiency, increasing adoption of minimally invasive procedures, technological advancements, and favorable reimbursement policies. Growing awareness and demand for effective venous outflow restoration are expected to drive significant growth.

Wallstent Technology

Wallstent Technology is designed to address iliofemoral vein obstructions, particularly in the upper pelvic area extending to the groin. T. The Wallstent system typically comprises a braided metallic (Elgiloy) wire stent and a catheter device for over-the-wire stent delivery. It is especially effective in treating conditions resulting from fibrous blood clots or vein compression, which can restrict blood circulation from the leg, causing swelling and walking pain. The increasing prevalence of such conditions and the effectiveness of Wallstent Technology in restoring venous patency contribute to its growing adoption.

Venous Stents Market, Segmentation by Stent Design

The Venous Stents Market has been segmented by Stent Design into Braided, Laser-Cut, Open-Cell, and Closed-Cell.

Braided

Braided stents are constructed using interwoven wire mesh, offering exceptional flexibility and conformability to complex venous anatomies. This design is particularly beneficial for treating tortuous or irregularly shaped veins, ensuring optimal vessel wall apposition. While specific market share data is limited, braided stents are favored in cases requiring enhanced maneuverability and adaptability.

Laser-Cut

Laser-cut stents are manufactured by precisely cutting patterns into metal tubes, typically made of nitinol or stainless steel. This design allows for high radial strength and structural integrity, making them suitable for treating straightforward venous lesions. The precision of laser-cutting technology ensures consistent stent geometry and deployment accuracy.

Open-Cell

Open-cell stents feature larger gaps between struts, providing enhanced flexibility and conformability to the vessel's natural curvature. This design facilitates better side-branch access and reduces the risk of stent migration. In 2022, open-cell stents held a significant market share of approximately 88.1%, reflecting their widespread adoption in treating various venous conditions.

Closed-Cell

Closed-cell stents have smaller gaps between struts, offering increased radial force and scaffolding capabilities. This design is advantageous in providing uniform vessel support and minimizing the risk of tissue prolapse through the stent. Closed-cell stents are often utilized in scenarios requiring enhanced structural stability and precise lesion coverage.

Venous Stents Market, Segmentation by Material

The Venous Stents Market has been segmented by Material into Nitinol, Elgiloy and Stainless Steel.

Nitinol

Nitinol, a nickel-titanium alloy, is renowned for its superelasticity and shape memory properties, making it highly suitable for venous stents. Its ability to conform to the vein's natural movements reduces the risk of stent migration and enhances patient comfort. Nitinol's biocompatibility and corrosion resistance further contribute to its widespread adoption in the market.

Elgiloy

Elgiloy, a cobalt-chromium-nickel alloy, offers exceptional strength and flexibility, making it ideal for stents requiring high radial force. Its fatigue resistance ensures long-term durability, particularly in challenging venous anatomies. Elgiloy's biocompatibility and resistance to corrosion make it a preferred choice for specific clinical applications.

Stainless Steel

Stainless steel, particularly the 316L grade, has been traditionally used in venous stents due to its mechanical strength and cost-effectiveness. While it offers reliable structural support, its rigidity compared to newer materials may limit its use in anatomies requiring greater flexibility. Nonetheless, stainless steel remains a viable option in various venous interventions.

Venous Stents Market, Segmentation by Disease

The Venous Stents Market has been segmented by Disease into Chronic Deep Vein, Thrombosis, Post Thrombotic Syndrome and Others.

Chronic Deep Vein Thrombosis

Chronic Deep Vein Thrombosis (DVT) is a significant contributor to the venous stents market, accounting for approximately 47.1% of the total revenue. This condition involves the formation of blood clots in deep veins, leading to venous obstruction and chronic pain. Venous stents are increasingly utilized to restore normal blood flow and alleviate symptoms associated with chronic DVT.

Post-Thrombotic Syndrome

Post-Thrombotic Syndrome (PTS) is a long-term complication of DVT, characterized by pain, swelling, and skin changes in the affected limb. PTS affects approximately 20–50% of patients within two years following a DVT episode. The use of venous stents in PTS management aims to improve venous outflow and reduce the severity of symptoms, thereby enhancing patient quality of life.

Others

The 'Others' category encompasses various conditions such as May-Thurner Syndrome, Nutcracker Syndrome, and complications arising from hemodialysis access. These conditions, while less prevalent, contribute to the overall demand for venous stents. Advancements in stent technology and increased awareness among healthcare professionals are driving the adoption of venous stents in these niche applications.

Venous Stents Market, Segmentation by Geography

In this report, the Venous Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Regions and Countries Analyzed in this Report

Legend

North America

Rest of North America

Europe

Rest of Europe

Asia Pacific

Rest of Asia Pacific

Middle East and Africa

Rest of Middle East and Africa

Latin America

Rest of Latin America

Rest of the World

Venous Stents Market Share (%), by Geographical Region

North America

North America led the venous stents market in 2023, accounting for over 40% of the global share. This dominance is attributed to a high prevalence of venous disorders, advanced healthcare infrastructure, and significant investments in research and development. The presence of key market players and favorable reimbursement policies further bolster the region's market position.

Europe

Europe held a substantial market share of approximately 30% in 2023, driven by a growing incidence of venous diseases and the adoption of minimally invasive procedures. The region benefits from a well-established healthcare system and increased awareness of venous stenting as an effective treatment option.

Asia Pacific

Asia Pacific is the fastest-growing region in the venous stents market, projected to expand at a CAGR of 12% between 2024 and 2032. Factors contributing to this growth include a rising geriatric population, increasing prevalence of venous disorders, and improvements in healthcare infrastructure. Countries like China and India are witnessing heightened demand for advanced vascular treatments.

Middle East and Africa

The Middle East and Africa region accounted for around 8% of the global venous stents market in 2023. Market growth is supported by increasing healthcare investments, rising awareness of venous diseases, and the gradual adoption of modern medical technologies. Efforts to improve healthcare access and infrastructure are expected to further drive market expansion.

Latin America

Latin America contributed approximately 7% to the global venous stents market in 2023. The region's growth is fueled by a growing burden of chronic venous diseases, increased healthcare expenditure, and the adoption of minimally invasive treatments. Countries like Brazil and Mexico are leading the regional market due to their expanding healthcare sectors.

Market Trends

This report provides an in depth analysis of various factors that impact the dynamics of Global Venous Stents Market. These factors include; Market Drivers, Restraints and Opportunities.

Drivers, Restraints and Opportunity Analysis

Drivers

Increasing Prevalence of Venous Disorders
Technological Advancements in Stent Design
Growing Adoption of Minimally Invasive Procedures - One of the key factors driving the adoption of minimally invasive procedures is the continuous evolution of interventional technologies and techniques, enabling clinicians to perform complex venous interventions with precision and efficacy. Advances in imaging modalities, such as intravascular ultrasound (IVUS) and fluoroscopy, provide real-time visualization of venous anatomy, facilitating accurate stent placement and optimizing procedural outcomes. Additionally, the development of dedicated venous stent systems with enhanced flexibility, radial strength, and navigability further enhances the feasibility and success rates of minimally invasive venous interventions.

The shift towards minimally invasive approaches aligns with broader healthcare trends favoring outpatient and ambulatory care models, thereby reducing healthcare costs and optimizing resource utilization. Minimally invasive venous procedures can often be performed in specialized outpatient centers or catheterization laboratories, minimizing the need for hospitalization and enabling patients to resume normal activities sooner.

The growing emphasis on patient-centered care and shared decision-making drives demand for minimally invasive options that offer favorable cosmetic outcomes, reduced pain, and enhanced quality of life. Patients increasingly prefer less invasive treatment alternatives that minimize disruption to their daily routines and preserve their independence.

Restraints

Lack of Reimbursement Policies in Some Regions
Risk of Stent Migration and Thrombosis
Limited Clinical Evidence Supporting Long-term Efficacy - One challenge contributing to this limitation is the relatively recent emergence of venous stenting as a standard treatment modality for venous diseases. Compared to arterial stents, which have been extensively studied and refined over decades, venous stents have undergone fewer clinical trials and have a shorter track record in real-world clinical practice. As a result, there is a lack of consensus regarding optimal stent design, sizing, and deployment techniques, as well as uncertainty regarding the risk of stent migration, fracture, and thrombosis over extended follow-up periods.

The heterogeneity of venous disorders and patient populations poses challenges in conducting large-scale, prospective studies with long-term follow-up. Venous diseases encompass a broad spectrum of pathologies, ranging from acute thrombotic events to chronic venous insufficiency, each with distinct etiologies, clinical presentations, and prognoses. Consequently, designing clinical trials that capture the diverse clinical manifestations and long-term outcomes of venous stent placement remains a formidable task.

The retrospective nature of many existing studies and the variability in reporting standards for venous stent outcomes further complicate efforts to synthesize evidence and draw definitive conclusions regarding long-term efficacy and safety. Without comprehensive, standardized data collection and rigorous comparative studies, clinicians and policymakers may hesitate to adopt venous stenting as a first-line treatment option, particularly in cases where alternative interventions, such as conservative management or surgical procedures, may be considered.

Opportunities

Untapped Market Potential in Emerging Economies
Development of Drug-Eluting and Bioresorbable Stents
Expansion of Indications for Venous Stent Placement - One notable area of expansion is the treatment of May-Thurner syndrome, a condition characterized by compression of the left iliac vein by the overlying right iliac artery, leading to venous outflow obstruction and predisposition to DVT. Venous stent placement in May-Thurner syndrome aims to alleviate venous compression, restore normal venous flow, and reduce the risk of recurrent thrombosis, thereby offering a potential solution for patients with this often-overlooked condition.

The advent of drug-eluting stents and bioresorbable scaffolds has opened up new avenues for the management of venous disorders, including the prevention of stent restenosis and the promotion of venous wall healing. These innovative technologies hold promise for extending the durability of stent patency and minimizing the need for repeat interventions, thus enhancing long-term clinical outcomes for patients undergoing venous stent placement.

The exploration of venous stent placement in non-thrombotic venous disorders, such as post-thrombotic syndrome and venous ulcers, represents a frontier for future research and clinical innovation. By addressing underlying venous pathology and optimizing venous hemodynamics, venous stents may offer a novel therapeutic approach for improving wound healing and reducing the burden of chronic venous disease in affected individuals.

Competitive Landscape Analysis

Key players in Global Venous Stents Market include:

Gore Medical
Cook Medical
Boston Scientific Corporation
Becton, Dickinson and Company
Medtronic Plc

In this report, the profile of each market player provides following information:

Company Overview and Product Portfolio
Key Developments
Financial Overview
Strategies
Company SWOT Analysis

Introduction
1. Research Objectives and Assumptions
2. Research Methodology
3. Abbreviations
Market Definition & Study Scope
Executive Summary
1. Market Snapshot, By Technology
2. Market Snapshot, By Stent Design
3. Market Snapshot, By Material
4. Market Snapshot, By Disease
5. Market Snapshot, By Region
Venous Stents Market Dynamics
1. Drivers, Restraints and Opportunities
  1. Drivers
    1. Increasing Prevalence of Venous Disorders
    2. Technological Advancements in Stent Design
    3. Growing Adoption of Minimally Invasive Procedures
  2. Restraints
    1. Lack of Reimbursement Policies in Some Regions
    2. Risk of Stent Migration and Thrombosis
    3. Limited Clinical Evidence Supporting Long-term Efficacy
  3. Opportunities
    1. Untapped Market Potential in Emerging Economies
    2. Development of Drug-Eluting and Bioresorbable Stents
    3. Expansion of Indications for Venous Stent Placement
2. PEST Analysis
  1. Political Analysis
  2. Economic Analysis
  3. Social Analysis
  4. Technological Analysis
3. Porter's Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitutes
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Segmentation
1. Venous Stents Market, By Technology, 2021 - 2031 (USD Million)
  1. Iliac Vein Stent Technology
  2. Wallstent Technology
2. Venous Stents Market, By Stent Design, 2021 - 2031 (USD Million)
  1. Braided
  2. Laser-Cut
  3. Open-Cell
  4. Closed-Cell
3. Venous Stents Market, By Material, 2021 - 2031 (USD Million)
  1. Nitinol
  2. Elgiloy
  3. Stainless Steel
4. Venous Stents Market, By Disease, 2021 - 2031 (USD Million)
  1. Chronic Deep Vein
  2. Thrombosis
  3. Post Thrombotic Syndrome
  4. Others
5. Venous Stents Market, By Geography, 2021 - 2031 (USD Million)
  1. North America
    1. United States
    2. Canada
  2. Europe
    1. Germany
    2. United Kingdom
    3. France
    4. Italy
    5. Spain
    6. Nordic
    7. Benelux
    8. Rest of Europe
  3. Asia Pacific
    1. Japan
    2. China
    3. India
    4. Australia & New Zealand
    5. South Korea
    6. ASEAN (Association of South East Asian Countries)
    7. Rest of Asia Pacific
  4. Middle East & Africa
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
  5. Latin America
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
Competitive Landscape
1. Company Profiles
  1. Gore Medical
  2. Cook Medical
  3. Boston Scientific Corporation
  4. Becton, Dickinson and Company
  5. Medtronic Plc
Analyst Views
Future Outlook of the Market